FDA approves home AMD monitoring device Notal Vision has received FDA approval for the firm's ForeseeHome age-related macular degeneration (AMD) analysis device.

The ForeseeHome AMD Monitor is the first device of its kind in the eye care industry that allows patients with the dry form of AMD to monitor themselves for signs of an oncoming choroidal neovascularization in the convenience and comfort of their own home with data transmitted to the patient's eye care physician and the Notal Vision Data Monitoring Center.

Notal Vision plans to introduce the ForeseeHome AMD Monitor to the market in Q1 2010, with continued investment in clinical research and product development.

Read more...
Notal Vision